4.4 Article

Applicability of the AHA/ACC/HRS Guideline for Implantable Cardioverter Defibrillator Implantation in Japanese Patients With Cardiac Sarcoidosis

期刊

JACC-CLINICAL ELECTROPHYSIOLOGY
卷 7, 期 11, 页码 1410-1418

出版社

ELSEVIER
DOI: 10.1016/j.jacep.2021.04.009

关键词

cardiac sarcoidosis; guideline; implantable cardioverter defibrillator; Japanese; ventricular arrhythmias

资金

  1. Japan Society for the Promotion of Science [15K19402]
  2. Japan Heart Foundation
  3. Grants-in-Aid for Scientific Research [15K19402] Funding Source: KAKEN

向作者/读者索取更多资源

The study aimed to assess the ICD recommendations for Japanese patients with cardiac sarcoidosis (CS) based on AHA/ACC/HRS guidelines. It found that ICD implantation may be applicable to patients requiring a permanent pacemaker or with late gadolinium enhancement, regardless of left ventricular ejection fractions (LVEF) <= 35%.
OBJECTIVES This study aimed to assess, among Japanese patients with cardiac sarcoidosis (CS), the implantable cardioverter-defibrillator (ICD) recommendations from the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (SCD). BACKGROUND Although ICDs are used to prevent SCD from ventricular tachycardia or ventricular fibrillation (VT/VF) in patients with CS, the generalizability of the AHA/ACC/HRS guidelines for Japanese patients with CS remains unclear. METHODS This study examined 188 consecutive patients with CS in 2 tertiary hospitals between 1979 and 2020. Patients were followed for a primary outcome of VT/VF or SCD. RESULTS During a median follow-up of 5.68 years, the primary outcome occurred in 44 patients (23%). Patients with a Class I recommendation for ICD implantation showed the highest incidence of the primary outcome among patients in whom the guideline recommendations for ICD implantation were used (log-rank test; p = 0.03). However, compared with patients with left ventricular ejection fractions (LVEFs) <= 35%, there was no significant difference in the incidence of the primary outcome among patients with LVEFs >35% and those who required a permanent pacemaker (p = 0.31); similar results were observed in those with LVEFs > 35% and late gadolinium enhancement during cardiovascular magnetic resonance imaging (p = 0.22). CONCLUSIONS The American guideline recommendations for ICD implantation might be applicable to Japanese patients with CS. Implantation of an ICD may need to be considered in these patients if they require a permanent pacemaker or have late gadolinium enhancement, regardless of LVEF. (C) 2021 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据